Arthrosi Therapeutics has completed a series E funding round, amassing $153m, earmarked to advance the clinical development of pozdeutinurad.

Enrollment complete in the replicate REDUCE 1 and REDUCE 2 Phase 3 studies with pivotal data expected in Q2 2026 SAN DIEGO, Oct. 8, 2025 /PRNewswire/ -- Arthrosi Therapeutics, Inc., a late-stage ...

San Diego-based Arthrosi Therapeutics, a biotech developing highly potent and selective next generation URAT1 inhibitor to reduce serum urate (sUA) levels, flares, and dissolve tophi in gout and ...

High uric acid levels can lead to joint pain and gout but these 6 yoga poses can naturally help balance it by improving metabolism and detoxification.